Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Resverlogix Establishes Clinical & Scientific Advisory Board

Published: Wednesday, December 26, 2012
Last Updated: Wednesday, December 26, 2012
Bookmark and Share
Dr. Bengt Winblad appointed Chairman of the clinical & scientific advisory board.

Resverlogix Corp. has announced the formation of a clinical & scientific advisory board to support the clinical development of its lead drug candidate RVX-208 and follow-on bromodomain inhibitors in neurodegenerative diseases such as Alzheimer's disease, mild cognitive impairment and other dementias.

The board, chaired by Dr. Bengt Winblad, will provide insight and guidance on all aspects of the development program.

"We believe cardiovascular and neurodegenerative health is linked by lipoproteins such as Apolipoprotein A-I (ApoA-I)," said Dr. Jan Johansson, senior vice president of medical affairs at Resverlogix.

Dr. Johansson continued, "A clinical program will further our understanding of how RVX-208, an epigenetic BET bromodomain inhibitor which increases production of Apo A-I, may affect neurodegenerative diseases such as early dementia or mild cognitive impairment."

Donald McCaffrey, president and chief executive officer of Resverlogix, added, "RVX-208 is the first BET bromodomain inhibitor that has emerged from Resverlogix' epigenetic drug discovery platform and moved into the clinic. It is currently in Phase 2b clinical development in patients with high-risk cardiovascular disease and we are eager to evaluate it and our other BET inhibitor compounds in other disease states."

Bengt Winblad, M.D., Ph.D., professor of geriatric medicine and chief physician at the Karolinska University Hospital, said, "Recent studies are providing evidence of the link between poor cognition, memory and low levels of cardio-protective factors such as ApoA-I. I am looking forward to working with Resverlogix and studying RVX-208 in patients with neurodegenerative diseases."

Resverlogix plans to initiate a Phase 2 trial of RVX-208 in patients with mild cognitive impairment in the second half of 2013.

Appointed members of the clinical & scientific advisory board include:
Bengt Winblad, M.D., Chairman: Dr. Winblad is professor of geriatric medicine and chief physician at the Karolinska University Hospital, Huddinge and the Karolinska Institute in Stockholm, Sweden.

Professor Winblad is co-chair of the European Alzheimer Disease Consortium (EADC) and chairs the Medical Scientific Advisory Panel of the Alzheimer Disease International (ADI). In 2009, Dr. Winblad was ranked the world's most prolific researcher in the Alzheimer's disease field (J Alzheimer's Disease 2009).

Jeff Cummings, M.D., Sc.D.: Dr. Cummings is director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas and Cleveland. Dr. Cummings received the Ronald and Nancy Reagan Research Award from the National Alzheimer's Association in 2008.

Henrik Zetterberg, M.D., Ph.D.: Dr. Zetterberg is professor of neurochemistry at the University of Gothenburg. He was a Fulbright Scholar and research fellow in neurology at the Harvard Institutes of Medicine, Boston between 2004 and 2005. Dr. Zetterberg is an established leader in the field of neurochemistry, biomarkers and diagnostics.

Rada Koldamova, M.D., Ph.D.: Dr. Koldamova is an associate professor and lead researcher at the School of Public Health, University of Pittsburgh's Koldamova & Lefterov lab. Her interest is in cellular and molecular mechanisms of neurodegeneration, the role of ABCA1 transporter and apolipoproteins A-I and E in the pathogenesis of Alzheimer's disease.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Resverlogix Commences Dosing in Phase 3 Clinical Trial BETonMACE
First patient randomized in BETonMACE Phase 3 trial in high-risk coronary artery disease and type 2 diabetes mellitus patients.
Tuesday, November 24, 2015
Resverlogix Presents Important New Data at the ASN Kidney Week Conference
Apabetalone and Alkaline Phosphatase data highlighted in multiple presentations.
Saturday, November 21, 2015
Resverlogix Commences Phase 3 Clinical Trial BETonMACE with Apabetalone
Apabetalone will be evaluated in a Phase 3 clinical trial in high-risk coronary artery disease and type 2 diabetes mellitus patients.
Saturday, October 31, 2015
Resverlogix Provides Research and Development Update
Company has presented an Update for RVX-208 "apabetalone" on September 25, 2015 in New York City.
Tuesday, October 06, 2015
Resverlogix Announces the Commencement of an Orphan Disease Program
Apabetalone (RVX-208) to be tested in a proof-of-concept pilot trial in a complement mediated disease Paroxysmal Nocturnal Hemoglobinuria (PNH) in 2016.
Saturday, September 26, 2015
Resverlogix Presents New Data at the ESC Congress 2015
Company presents new data on RVX-208 "apabetalone" a selective BET inhibitor.
Tuesday, September 01, 2015
International Clinical Steering Committee Announced from Resverlogix
Professor Kausik Ray to chair clinical steering committee for landmark epigenetic BET inhibition trial.
Saturday, August 08, 2015
Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority
Company expects to launch the upcoming BETonMACE Phase 3 clinical trial.
Tuesday, June 23, 2015
Resverlogix Presents New Data at 52nd Annual ERA-EDTA Congress
RVX-208, the first selective bromodomain extra-terminal (BET) protein inhibitor, significantly reduces alkaline phosphatase (ALP) levels in patients with high vascular risk.
Thursday, June 04, 2015
Resverlogix and Hepalink Announce a Combination Licensing and Equity Arrangement
The deal structure involves CAD$50 million in equity investments, and future China sales milestones and licensing royalties that could represent in excess of US$400 million.
Thursday, May 07, 2015
Resverlogix Presents at Biotech Showcase During JP Morgan Week
Donald McCaffrey share developments of the Company's proposed new phase 3 clinical trial BETONMACE.
Thursday, January 15, 2015
Resverlogix Appoints Senior Vice President of Clinical Development
Appointment of Michael T. Sweeney, M.D., as senior vice president.
Tuesday, November 04, 2014
RVX-208 Reduces MACE Significantly in Patients with Diabetes Mellitus
In addition, preliminary results from an Australian sponsored trial have yet to verify whether the mechanism of RVX-208 action may affect glucose metabolism.
Thursday, July 24, 2014
Resverlogix Secures an Additional $30 Million from Citibank Loan
Special meeting of shareholders called to approve.
Saturday, July 05, 2014
Resverlogix Granted European Patent
European Patent office grants RVX-208 patent until 2027.
Tuesday, March 18, 2014
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Diabetes Missing Link Discovered
Researchers from the University of Auckland have shown that beta catenin plays a vital role in the control of insulin release from the pancreas.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
Biological Link between the Gut Microbiome and Parkinson’s Disease
The findings suggest that targeting the gut microbiome may provide a new approach for diagnosing and treating Parkinson’s disease.
How the Brain Recognizes Faces
Machine-learning system spontaneously reproduces aspects of human neurology.
Boosting Effectiveness of Asthma Therapy
A team of scientists from UCSF has developed a new treatment to dampen bronchospasm.
Improved Stability, Shelf Life of Protein Drugs
Study improves protein drug stability and extend their shelf life by tested a novel route for non-covalent protein modification.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!